Cydectin 0.1%

1 x 1 l

Oral solution

Active substance

Moxidectin : 1 mg/ml

ATC code

QP54AB02 Moxidectin

QP54AB Milbemycins

QP54A Macrocyclic lactones

QP54 Endectocides

QP Antiparasitic products, insecticides and repellents

Species

Sheep.

Indications

For the treatment and prevention of infections caused by:

- Adult and immature gastro-intestinal nematodes

• Haemonchus contortus (including inhibited larvae)

• Ostertagia (Teladorsagia) circumcincta (including inhibited larvae)

• Ostertagia (Teladorsagia) trifurcata

• Trichostrongylus axei (including inhibited larvae)

• Trichostrongylus colubriformis

• Trichostrongylus vitrinus

• Nematodirus battus

• Nematodirus spathiger

• Nematodirus filicolis (adults only)

• Strongyloides papillosus (larval stages only)

• Cooperia curticei (adults only)

• Cooperia oncophora

• Oesophagostomum columbianum

• Oesophagostomum venulosum (adults only)

• Chabertia ovina

• Trichuris ovis (adults only)

- Adult respiratory tract nematode

• Dictyocaulus filaria

- The veterinary medicinal product has a persistent effect in preventing reinfection:

• for 5 weeks by Ostertagia (Teladorsagia) circumcincta and Haemonchus contortus

• for 4 weeks by Oesophagostomum columbianum

Dose to be administered and administration route

Oral use.

Should be given as a single oral drench of 1 ml/5 kg live bodyweight, equivalent to 200 µg moxidectin/kg live bodyweight, using any standard drenching equipment.

Underdosing could result in ineffective use and may favour resistance development.

To ensure administration of a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonably homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.

Accuracy of the dosing should be thoroughly checked. Do not mix with other products.

Adverse reactions

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.